Genflow Biosciences reaches key milestone with EU patent

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company's achievement in securing a major European patent. The newly published patent strengthens Genflow’s intellectual property around its sirtuin 6 variant — a core element of its longevity therapeutic platform. Leire described the development as a “major step,” noting it creates a strong defensive barrier against competition. “We are now in the final phase of securing our cornerstone intellectual property,” he said. This form of protection is vital for small biotech firms like Genflow, particularly as it enhances the company’s attractiveness to potential pharmaceutical partners. Leire emphasised that, with this patent in place, Genflow now has the IP foundation needed to engage pharma players seriously. He explained that the company is unlikely to fund Phase 3 trials independently, making partnerships essential. “You need to have a strong IP protection. Now we have it with a long life,” he added. Looking ahead, Leire pointed to the upcoming efficacy readout from the company’s Dutch study as the next major milestone. The company also hopes the patent will help accelerate early-stage deals around other therapeutic targets, including muscle atrophy (mass), sarcopenia, and glaucoma. Watch the full interview to hear more on Genflow’s progress in developing its innovative longevity therapies. For more exclusive interviews and company updates, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications to stay up to date. # GenflowBiosciences #LongevityTherapies #BiotechNews #PharmaPartnership #Sirtuin6 #IntellectualProperty #EUPatent #Sarcopenia #AgingResearch #BiotechInnovation #ClinicalTrials #HealthcareInvesting